aTyr Pharma Reports Q3 GAAP EPS of -$7.43, Missing Estimates by $3.43
aTyr Pharma (ATYR) reported third-quarter earnings that significantly missed analyst expectations, posting a GAAP Earnings Per Share (EPS) of -$7.43. This result represents a miss of $3.43 compared to consensus estimates. Despite the quarterly loss, the company reported a strong liquidity position with $50.3 million in cash, cash equivalents, restricted cash, and available-for-sale investments as of September 30, 2026. Management stated that this capital is expected to fund current operations into late 2028.
Tickers: $ATYR
Topics: cash runway EPS miss financial results quarterly earnings